Systemic therapy of brain metastases: non–small cell lung cancer, breast cancer, and melanoma

MC Chamberlain, CS Baik, VK Gadi, S Bhatia… - Neuro …, 2017 - academic.oup.com
Brain metastases (BM) occur frequently in many cancers, particularly non–small cell lung
cancer (NSCLC), breast cancer, and melanoma. The development of BM is associated with …

Existing and emerging technologies for tumor genomic profiling

LE MacConaill - Journal of Clinical Oncology, 2013 - ascopubs.org
Ongoing global genome characterization efforts are revolutionizing our knowledge of cancer
genomics and tumor biology. In parallel, information gleaned from these studies on driver …

Imatinib for Melanomas Harboring Mutationally Activated or Amplified KIT Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin

FS Hodi, CL Corless, A Giobbie-Hurder… - Journal of clinical …, 2013 - ascopubs.org
Purpose Amplifications and mutations in the KIT proto-oncogene in subsets of melanomas
provide therapeutic opportunities. Patients and Methods We conducted a multicenter phase …

High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing

N Wagle, MF Berger, MJ Davis, B Blumenstiel… - Cancer discovery, 2012 - AACR
Abstract Knowledge of “actionable” somatic genomic alterations present in each tumor (eg,
point mutations, small insertions/deletions, and copy-number alterations that direct …

Personalized oncology through integrative high-throughput sequencing: a pilot study

S Roychowdhury, MK Iyer, DR Robinson… - Science translational …, 2011 - science.org
Individual cancers harbor a set of genetic aberrations that can be informative for identifying
rational therapies currently available or in clinical trials. We implemented a pilot study to …

Prevalence of class I–III BRAF mutations among 114,662 cancer patients in a large genomic database

J Owsley, MK Stein, J Porter, GK In… - Experimental …, 2021 - journals.sagepub.com
BRAF mutations are relatively common in many cancers, particularly melanoma, colorectal
cancer, and thyroid cancer and to a lesser extent in lung cancer. These mutations can be …

BRAF L597 Mutations in Melanoma Are Associated with Sensitivity to MEK Inhibitors

KB Dahlman, J **
C Beadling, TL Neff, MC Heinrich, K Rhodes… - The Journal of Molecular …, 2013 - Elsevier
There is growing demand for routine identification of actionable mutations in clinical cancer
specimens. Genoty** platforms must provide rapid turnaround times and work effectively …